Ratings MeiraGTx Holdings plc

Equities

MGTX

KYG596651029

Real-time Estimate Cboe BZX Other stock markets 01:06:01 2024-05-14 pm EDT			5-day change	1st Jan Change
5.195 ^USD	+1.07%		-3.25%	-25.85%

May. 09	Earnings Flash (MGTX) MEIRAGTX Reports Q1 Revenue $697,000	MT
May. 09	MeiraGTx Holdings plc Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the past twelve months, EPS forecast has been revised upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
MEIRAGTX HOLDINGS PLC	-25.85%	331M	C
VERTEX PHARMACEUTICALS INCORPORATED	+3.99%	111B	B+
REGENERON PHARMACEUTICALS, INC.	+11.45%	105B	B+
BIONTECH SE	-12.69%	22.34B	B+
ARGENX SE	-3.70%	21.93B	B
GENMAB A/S	-6.03%	18.59B	A-
WUXI APPTEC CO., LTD.	-35.21%	18.12B	A-
BEIGENE, LTD.	-10.26%	16.96B	B
NEUROCRINE BIOSCIENCES, INC.	+2.96%	13.7B	C+
SAREPTA THERAPEUTICS, INC.	+36.80%	12.45B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes